drugset
drugset / Trial / NCT05553808

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

NCT05553808 ↗

Phase 2 Completed 105 enrolled GlaxoSmithKline iTeos Belgium SA · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.

Timeline

Start
2019-01-24
Primary completion
2021-09-23
Completion
2021-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Feladilimab Monoclonal antibody — Intravenous
Background Docetaxel Small molecule — Intravenous

Indications

neoplasm